Advertising
Showing 1 to 15 of 220 entries

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Mar 24/22, Up 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has triggered its stop at $855. To remain disciplined we recommend covering the position at this time. This will result in a net investment gain of 8%, when combined with previous buy recommendations.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Mar 24/22, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $80) to $85.
biotechnology / pharmaceutical
BUY
Reasonable and sustainable multiple of 12x and very good dividend. Major drug is patent-protected until at least 2026, plus great drugs in pipeline.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick May 08/20, Up 36%) Loves it. A bit pricey here. Model price of $122.65, a 31% upside. In bear markets, people go for predictable earnings. Good bear market stock. Wait for a pullback to buy, under $70. Over 3% yield.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Mar 24/22, Up 15%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has achieved its $92.50 target. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $74) to $80.
biotechnology / pharmaceutical
TOP PICK
Growth focused, but a real business. Safety. Second-largest in animal health, diversified oncology. Visibility and pricing power. Roche's miss in immunotherapy reinforces MRK's leadership position in that area. Not expensive. 13x earnings for near double-digit EPS growth. Yield is 3.09%. (Analysts’ price target is $96.34)
biotechnology / pharmaceutical
TOP PICK
Their major drug in oncology treats cancer and will earn $18 billion in revenue this year. Trades at 12x earnings and pays a large dividend. MRK has a strong balance sheet, their drug pipeline promises future growth, their balance sheet is strong, and they can resist hot inflation. (Analysts’ price target is $96.34)
biotechnology / pharmaceutical
BUY
options There's been a huge spike in options in healthcare stocks. Merck started seeing options activity in late March. Today sees 14,000 of the May $87.50 calls for $1.50.
biotechnology / pharmaceutical
BUY
Some growth, especially in its blockbuster drug, which makes up 1/3 of total revenue. An uncomfortable concentration, but the patents are long-dated. Good dividend, AAA balance sheet, reasonable multiple at 11x.
biotechnology / pharmaceutical
BUY
He's long this. You're finally getting a technical breakout. The stock is at the highest levels of the year. Take advantage of the valuation discount for the healthcare sector compared to the S&P.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O’Reilly With several developmental cancer drugs continuing to make good progress, we again reiterate this $195 billion marketcap global drug manufacturer as a TOP PICK. Recently reported earnings beat expectations by over 20% and the company is managing a ROE over 45%. Trading at 16x forward earnings, compared with its peers at 21x, it is good value here. It pays a good dividend, backed by payout ratio under 55% of cash flow. We recommend trailing up the stop (from $70) to $74, looking to achieve $92.50 -- upside potential of 15%. Yield 3.4% (Analysts’ price target is $92.38)
biotechnology / pharmaceutical
BUY
It trades at 12x earnings with a solid growth rate, based on their major oncology drug. Also, their drug pipeline is solid. Dividend is healthy.
biotechnology / pharmaceutical
HOLD
Good large cap with reasonable growth. Really likes its diversity. Oncology, diabetes, immunology, globally #2 in animal health. Competition from BMY and LLY. Lacklustre R&D. Happy to hold through the volatility.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jan 10/20, Down 3%) Stock price popped on news of therapeutic pill. We're in a medical emergency, yet drug space is languishing, quite extraordinary. Lots of value. Model price of $146, 90% upside. Yield is 3.4%
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly This $195 billion marketcap global drug manufacturer has just received FDA emergency approval for an oral COVID-19 treatment and is reiterated as a TOP PICK. Japan just committed to 200,000 doses of the new pill. Trading at 11x forward earnings, compared with its peers at 19x, it is good value here. It pays an excellent dividend, backed by payout ratio under 50% of forward cash flow. We recommend trailing up the stop (from $65) to $70, looking to achieve $92.50 -- upside potential of 19%. Yield 3.59% (Analysts’ price target is $92.31)
biotechnology / pharmaceutical
Showing 1 to 15 of 220 entries

Merck & Company(MRK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 11

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 12

Stockchase rating for Merck & Company is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Merck & Company(MRK-N) Frequently Asked Questions

What is Merck & Company stock symbol?

Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N

Is Merck & Company a buy or a sell?

In the last year, 12 stock analysts published opinions about MRK-N. 11 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Merck & Company.

Is Merck & Company a good investment or a top pick?

Merck & Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Merck & Company.

Why is Merck & Company stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Merck & Company worth watching?

12 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.

What is Merck & Company stock price?

On 2022-06-24, Merck & Company (MRK-N) stock closed at a price of $93.13.